Profile data is unavailable for this security.
About the company
Stayble Therapeutics AB is a Sweden-based life science company developing an injectable treatment STA363 against chronic low back pain triggered by disc degeneration. The solutions are offered to the patients whose back pain persists after physiotherapy and drugs. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. Main focus of the Company is to develop STA363 as a new way of treatment for patients suffering from chronic disc-related low back pain. STA363 focuses on the two primary causes of pain in degenerative disc disease: leakage of inflammatory substances and disc instability. The mechanism of action of the treatment is to stabilize the disk segment and eliminate the possibility of disk leakage.
- Revenue in SEK (TTM)0.00
- Net income in SEK-8.42m
- Incorporated2015
- Employees2.00
- LocationStayble Therapeutics ABLennartTorstenssonsgatan 8GOETEBORG 411 33SwedenSWE
- Phone+46 730808397
- Websitehttps://staybletherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PCI Biotech Holding ASA | 4.37m | -19.12m | 6.73m | 7.00 | -- | 0.5771 | -- | 1.54 | -0.5502 | -0.5502 | 0.1256 | 0.3353 | 0.1676 | -- | 0.896 | 669,714.30 | -73.44 | -41.44 | -92.22 | -46.61 | -- | -- | -438.10 | -897.91 | -- | -- | 0.022 | -- | 125.25 | -6.43 | 19.19 | -- | -- | -- |
| Lidds AB | 0.00 | -5.58m | 6.82m | 1.00 | -- | 4.57 | -- | -- | -0.0409 | -0.0409 | 0.00 | 0.0109 | 0.00 | -- | -- | 0.00 | -99.68 | -64.76 | -119.64 | -76.72 | -- | -1,554.86 | -- | -2,637.08 | -- | -- | 0.00 | -- | -- | -- | 85.23 | -- | -65.39 | -- |
| Stayble Therapeutics AB | 0.00 | -8.42m | 12.60m | 2.00 | -- | 1.49 | -- | -- | -0.168 | -0.168 | 0.00 | 0.1314 | 0.00 | -- | -- | 0.00 | -78.98 | -78.82 | -83.99 | -92.78 | -- | -- | -- | -- | -- | -- | 0.0913 | -- | -- | -- | 47.69 | -- | -- | -- |
| Respiratorius AB (publ) | 0.00 | -7.12m | 12.68m | -- | -- | 0.3929 | -- | -- | -1.30 | -1.30 | 0.00 | 4.09 | 0.00 | -- | -- | -- | -21.57 | -- | -22.10 | -- | -- | -- | -- | -- | -- | -133.51 | 0.00 | -- | -- | -- | 3.36 | -- | -32.52 | -- |
| Fluicell AB | 2.68m | -9.86m | 12.98m | 11.00 | -- | 1.20 | -- | 4.84 | -7.18 | -7.18 | 1.95 | 7.86 | 0.1257 | -2.79 | 3.22 | 268,100.00 | -46.21 | -89.03 | -62.52 | -133.15 | 428.87 | 86.83 | -367.74 | -656.39 | 0.6057 | -- | 0.00 | -- | -44.31 | -5.66 | 41.59 | -- | 33.86 | -- |
| Gabather AB | 0.00 | -4.65m | 14.75m | 2.00 | -- | -- | -- | -- | -0.0384 | -0.0384 | 0.00 | -0.0111 | 0.00 | -- | -- | 0.00 | -209.07 | -67.13 | -- | -90.59 | -- | -- | -- | -- | -- | -76.57 | -- | -- | -- | -- | 17.84 | -- | -- | -- |
| Novakand Pharma AB | 0.00 | -51.90m | 15.75m | 5.00 | -- | 0.7865 | -- | -- | -0.4283 | -0.4283 | 0.00 | 0.1653 | 0.00 | -- | -- | 0.00 | -103.07 | -54.11 | -112.87 | -63.47 | -- | 70.00 | -- | -275,694.40 | -- | -- | 0.00 | -- | -- | -- | 31.32 | -- | -- | -- |
| ATTANA AB | 4.10m | -12.78m | 20.64m | 6.00 | -- | 0.6084 | -- | 5.03 | -0.0154 | -0.0154 | 0.0047 | 0.0132 | 0.1425 | -0.7611 | 1.02 | 656,600.00 | -44.37 | -37.91 | -61.34 | -48.09 | 161.16 | 189.23 | -311.34 | -305.50 | 0.6079 | -3.79 | 0.1315 | -- | -18.77 | -8.69 | 7.33 | -- | 8.51 | -- |
| Lumito AB (publ) | 81.51k | -48.06m | 27.53m | 8.00 | -- | 0.1986 | -- | 337.72 | -20.16 | -20.16 | 0.0253 | 40.27 | 0.0008 | -0.4224 | 0.0791 | 6,792.50 | -47.58 | -24.12 | -62.09 | -26.46 | 546.44 | -- | -58,966.97 | -138,894.00 | 0.2668 | -22.92 | 0.1994 | -- | -- | -- | -61.08 | -- | -30.66 | -- |
| Aptahem AB | 0.00 | -7.43m | 28.37m | -- | -- | 0.2308 | -- | -- | -0.6711 | -0.6711 | 0.00 | 3.77 | 0.00 | -- | -- | -- | -11.21 | -30.70 | -11.57 | -34.24 | -- | -- | -- | -- | -- | -44.15 | 0.00 | -- | -- | -- | 22.90 | -- | 88.99 | -- |
| Holder | Shares | % Held |
|---|---|---|
| FCG Fonder ABas of 31 Mar 2025 | 2.80k | 0.00% |
